Highlights Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Real-time Estimate Cboe BZX Other stock markets 12:12:11 14/05/2024 am IST			5-day change	1st Jan Change
7.37 ^USD	-1.07%		-3.10%	-38.81%

09/05	Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System	CI
07/05	Transcript : Pulse Biosciences, Inc., Q1 2024 Earnings Call, May 07, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System	09/05	CI
Pulse Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Sector Update: Health Care Stocks Slide Late Afternoon	02/04	MT
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	01/04	MT
Pulse Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Pulse Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/03	CI
Pulse Biosciences Gets FDA Clearance For Percutaneous Electrode System	09/03	MT
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System	08/03	CI
Pulse Biosciences, Inc. Announces Positive 60-Day Follow-Up Evaluations for Initial Patients Treated in the Cellfx Nspfa 360° Cardiac Catheter First-In-Human Feasibility Study	14/02	CI
Pulse Biosciences Files FDA Notification to Advance Testing of New Cardiac Clamp	02/01	MT
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp	02/01	CI
Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter	20/12	CI
Pulse Biosciences Cleared to Start Catheter Ablation Feasibility Trial; Set to File Application for Cardiac Clamp; Shares Rise	28/11	MT
Pulse Biosciences Shares Climb On Application for Percutaneous Electrode Review	21/11	DJ
Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode	21/11	CI
Pulse Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Pulse Biosciences, Inc. Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study	02/23/02	CI
Pulse Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Pulse Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Pulse Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Highlights

Filters